Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 10c, Raises FY EPS Guidance
Get Alerts JAZZ Hot Sheet
Price: $107.43 -0.82%
Revenue Growth %: +7.1%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +7.1%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.33, $0.10 better than the analyst estimate of $2.23. Revenue for the quarter came in at $306.6 million versus the consensus estimate of $302.9 million.
Jazz Pharmaceuticals sees FY2014 EPS of $8.20-$8.35, versus prior guidance of $8-$8.25 and the consensus of $8.17. Jazz Pharmaceuticals sees FY2014 revenue of $1.15-1.17 million, versus prior guidance of $1.125-1.165 million and the consensus of $1.16 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel (INTC) tops Q1 EPS by 3c; misses on guidance
- Snap (SNAP) Tops Q1 EPS by 29c, Offers Guidance
- FICO (FICO) Tops Q2 EPS by 33c, provides guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!